Immunohistochemical Study on the Expression of Topoisomerase II alpha and Glutathione S-Transferase pi in Acute Myeloid Leukemia.
- Author:
Byoung Kuk KIM
1
;
Yoon Sung JEONG
;
Chul Hun CHANG
;
Han Chul SON
;
Soon Ho KIM
;
Mee Young SOL
;
Eun Yup LEE
Author Information
1. Department of Clinical Pathology, Pusan Hae Dong Hospital.
- Publication Type:Original Article
- Keywords:
Acute myeloid leukemia;
Topoisomerase II alpha;
Glutathione S-transferase pi;
Immunohistochemistry;
Multidrug resistance
- MeSH:
Alkylating Agents;
Anthracyclines;
Bone Marrow;
Cell Line;
DNA Topoisomerases, Type II*;
Doxorubicin;
Drug Resistance, Multiple;
Drug Therapy;
Glutathione S-Transferase pi*;
Glutathione Transferase*;
Glutathione*;
Humans;
Immunohistochemistry;
Induction Chemotherapy;
Leukemia, Myeloid, Acute*;
Paraffin;
Podophyllotoxin
- From:Korean Journal of Clinical Pathology
1998;18(2):107-114
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Topoisomerase II (topo II) is a major target of anthracyclines and epipodophyllotoxins for anticancer treatment. The expression of topo II is low in drug resistant cell lines. High levels of glutathione S-transferase (GST)pi have been associated with emergence of cell lines resistant to alkylating agents or adriamycin. METHODS: By immunostaining with paraffin embedded bone marrow tissues, the expression of topo II alpha and GSTpi was investigated in 51 patients with acute myeloid leukemia (AML), and the relation of topo II alpha and GSTpi expression to treatment response in 29 patients with AML following induction chemotherapy was also evaluated. RESULTS: Topo II positive cells varied from less than 1% to 60% of leukemic cells and 20 (39.2%) were negative for topo II (positive cells<10%). Treatment response following chemotherapy was not related to topo II. 26 (51.0%) were positive for GSTpi. GSTpi expression was related to treatment resistance of the patients following chemotherapy. In the patients who showed both topo II alpha negative and GSTpi positive, the frequency of treatment resistance following chemotherapy was high. CONCLUSIONS: This study suggests that immunostaining of topo II alpha and GSTpi with the bone marrow paraffin sections of AML patients can be useful to predict the treatment response following chemotherapy and that further study including more patients with prospective study may substantiate topo II alpha and GSTpi as multidrug resistant markers.
